Research programme: PRS 300 Series - Pieris PharmaceuticalsAlternative Names: Anticalin®-antibody fusion proteins - Pieris Pharmaceuticals; PRS-300 Series A; PRS-300 Series B & C; PRS-300 Series D; PRS-332
Latest Information Update: 13 Feb 2017
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals
- Class Antibodies; Lipocalins
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer